Patents by Inventor Anastasia Khvorova

Anastasia Khvorova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
    Patent number: 11345917
    Abstract: This disclosure relates to novel targets for angiogenic disorders. Novel oligonucleotides are also provided. Methods of using the novel oligonucleotides for the treatment of angiogenic disorders (e.g., preeclampsia) are also provided.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: May 31, 2022
    Assignees: UNIVERSITY OF MASSACHUSETTS, BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Anastasia Khvorova, Melissa Moore, Anton A. Turanov, Ananth Karumanchi
  • OLIGONUCLEOTIDES FOR HTT-1A MODULATION
    Publication number: 20220090069
    Abstract: This disclosure relates to novel HTT-1A targeting sequences. Novel HTT-1A targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.
    Type: Application
    Filed: August 2, 2021
    Publication date: March 24, 2022
    Inventors: Anastasia Khvorova, Julia Alterman, Socheata Ly, Faith Conroy, Daniel O'Reilly
  • O-methyl rich fully stabilized oligonucleotides
    Patent number: 11279930
    Abstract: Novel oligonucleotides that are fully chemically stabilized are provided. Methods of using oligonucleotides that are fully chemically stabilized are also provided.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: March 22, 2022
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Anastasia Khvorova, Julia Alterman, Sarah Davis, Anton Turanov
  • Inhibition of MAP4K4 through RNAi
    Patent number: 11254940
    Abstract: RNAi constructs directed to MAP4K4 that demonstrate unexpectedly high gene silencing activities, and uses thereof are disclosed. The blunt-ended constructs have a double-stranded region of 19-49 nucleotides. The constructs have selective minimal modifications to confer an optimal balance of biological activity, toxicity, stability, and target gene specificity. For example, the strands may be modified (e.g., one or both ends of the sense strand is modified by 2?-O-methyl groups), such that the construct is not cleaved by Dicer or other RNAse III, the antisense strand may also be modified by a 2?-O-methyl group at the penultimate 5?-end nucleotide to greatly reduce off-target silencing.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: February 22, 2022
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Tod M. Woolf, Joanne Kamens, Anastasia Khvorova, William Salomon
  • CONJUGATED OLIGONUCLEOTIDES FOR TISSUE SPECIFIC DELIVERY
    Publication number: 20220042015
    Abstract: Provided herein are conjugated oligonucleotides that are characterized by efficient and specific tissue distribution with enhanced in vivo silencing efficacy.
    Type: Application
    Filed: July 16, 2021
    Publication date: February 10, 2022
    Inventors: Anastasia Khvorova, Annabelle Biscans
  • Oligonucleotide compounds for targeting huntingtin mRNA
    Patent number: 11230713
    Abstract: This disclosure relates to novel huntingtin targets. Novel oligonucleotides for the treatment of Huntington's disease are also provided.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: January 25, 2022
    Assignee: UNIVERSITY OF MASSACHUSETTS
    Inventors: Anastasia Khvorova, Neil Aronin, Julia Alterman
  • SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES WITH INCREASED STABILITY
    Publication number: 20220010309
    Abstract: This disclosure relates to the synthesis of novel modified oligonucleotides. The synthesis of novel phosphoramidites are also provided.
    Type: Application
    Filed: March 26, 2021
    Publication date: January 13, 2022
    Inventors: Anastasia Khvorova, Loïc Maurice René Jean Roux, Ken Yamada
  • SYNTHETIC OLIGONUCLEOTIDES HAVING REGIONS OF BLOCK AND CLUSTER MODIFICATIONS
    Publication number: 20210395739
    Abstract: This disclosure relates to novel modified oligonucleotides with increased stability. The universal modified nucleotide sequences to increase the stability of an oligonucleotide are also provided.
    Type: Application
    Filed: May 26, 2021
    Publication date: December 23, 2021
    Inventors: Anastasia Khvorova, Loïc Maurice René Jean Roux, Ken Yamada
  • MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING
    Publication number: 20210388348
    Abstract: Chemically modified crRNAs and tracrRNAs are provided. crRNAs and tracrRNAs with 5? and/or 3? conjugated moieties are provided. crRNAs and tracrRNAs with modifications in the repeat region of the crRNA or the anti-repeat region of the tracrRNA are provided. Methods of using the crRNAs and tracrRNAs for genome editing with a CRISPR nuclease and kits for performing the same are also provided.
    Type: Application
    Filed: May 12, 2021
    Publication date: December 16, 2021
    Inventors: Erik Joseph Sontheimer, Anastasia Khvorova, Jonathan Kenneth Watts, Nadia Amrani, Zexiang Chen, Matthew Hassler, Dimas Echeverria Moreno, Julia Frances Alterman, Scot Wolfe, Ken Yamada, Gitali Devi, Han Zhang
  • Methods and compositions for selecting siRNA of improved functionality
    Patent number: 11198870
    Abstract: Efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for TTR.
    Type: Grant
    Filed: February 5, 2020
    Date of Patent: December 14, 2021
    Assignee: THERMO FISHER SCIENTIFIC INC.
    Inventors: Anastasia Khvorova, Angela Reynolds, Devin Leake, William Marshall, Steven Read, Stephen Scaringe
  • OLIGONUCLEOTIDES FOR MAPT MODULATION
    Publication number: 20210363523
    Abstract: This disclosure relates to novel MAPT targeting sequences. Novel MAPT targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.
    Type: Application
    Filed: March 17, 2021
    Publication date: November 25, 2021
    Inventors: Anastasia Khvorova, Chantal Ferguson, Sarah Davis, Kathryn Monopoli
  • MODIFIED GUIDE RNAS FOR CRISPR GENOME EDITING
    Publication number: 20210363518
    Abstract: Chemically modified crRNAs and tracrRNAs are provided. crRNAs and tracrRNAs with 5? and/or 3? conjugated moieties are provided. crRNAs and tracrRNAs with modifications in the repeat region of the crRNA or the anti-repeat region of the tracrRNA are provided. Methods of using the crRNAs and tracrRNAs for genome editing with a CRISPR nuclease and kits for performing the same are also provided.
    Type: Application
    Filed: March 18, 2019
    Publication date: November 25, 2021
    Inventors: Erik Joseph SONTHEIMER, Anastasia KHVOROVA, Jonathan Kenneth WATTS, Aamir MIR, Julia Frances ALTERMAN, Matthew Ryan HASSLER, Michael Harry BRODSKY, Alexandre Jean-Marie DEBACKER
  • OLIGONUCLEOTIDES FOR SNCA MODULATION
    Publication number: 20210363524
    Abstract: This disclosure relates to novel SNCA targeting sequences. Novel SNCA targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.
    Type: Application
    Filed: March 17, 2021
    Publication date: November 25, 2021
    Inventors: Anastasia Khvorova, Chantal Ferguson, Sarah Davis, Kathryn Monopoli
  • OLIGONUCLEOTIDES FOR MSH3 MODULATION
    Publication number: 20210355491
    Abstract: This disclosure relates to novel MSH3 targeting sequences. Novel MSH3 targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.
    Type: Application
    Filed: April 20, 2021
    Publication date: November 18, 2021
    Inventors: Anastasia Khvorova, Chantal Ferguson
  • OLIGONUCLEOTIDES FOR TISSUE SPECIFIC GENE EXPRESSION MODULATION
    Publication number: 20210340533
    Abstract: This disclosure relates to a therapeutic combination of drugs for the treatment or management of a neurodegenerative disease, the combination comprising: a first conjugate comprising an RNA silencing agent and a first targeting agent that targets the first conjugate to the central nervous system, and a second conjugate comprising an antagonist of the RNA silencing agent and a second targeting agent that targets the second conjugate to a off-target tissue.
    Type: Application
    Filed: December 23, 2020
    Publication date: November 4, 2021
    Inventors: Anastasia Khvorova, Chantal Ferguson
  • DUAL-ACTING siRNA BASED MODULATION OF C9orf72
    Publication number: 20210340535
    Abstract: This disclosure relates to novel C9ORF72 targeting sequences. Novel sense and antisense dual-targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.
    Type: Application
    Filed: March 26, 2021
    Publication date: November 4, 2021
    Inventors: Anastasia Khvorova, Bruno Miguel da Cruz Godinho, James W. Gilbert
  • OLIGONUCLEOTIDES FOR PRNP MODULATION
    Publication number: 20210317460
    Abstract: This disclosure relates to novel PRNP targeting sequences. Novel PRNP targeting oligonucleotides for the treatment of neurodegenerative diseases are also provided.
    Type: Application
    Filed: February 26, 2021
    Publication date: October 14, 2021
    Inventors: Anastasia Khvorova, Zachary Kennedy
  • Reduced size self-delivering RNAI compounds
    Patent number: 11118178
    Abstract: The present invention relates to methods for in vivo administration of sd-rxRNA molecules.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: September 14, 2021
    Assignee: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, James Cardia
  • ARTIFICIAL EXOSOME COMPOSITION AND RELATED METHODS
    Publication number: 20210267893
    Abstract: Novel artificial exosomes and methods for producing novel artificial exosomes are provided. Methods of delivering cargo molecules to a cell using artificial exosomes are also provided.
    Type: Application
    Filed: January 21, 2021
    Publication date: September 2, 2021
    Inventors: Reka Agnes Haraszti, Anastasia Khvorova, Neil Aronin
  • RNA INTERFERENCE IN DERMAL AND FIBROTIC INDICATIONS
    Publication number: 20210261968
    Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal and fibrotic applications.
    Type: Application
    Filed: January 15, 2021
    Publication date: August 26, 2021
    Applicant: Phio Pharmaceuticals Corp.
    Inventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, Lyn Libertine, James Cardia, Karen G. Bulock